311P - Multinational survey study assessing genetic testing and counselling among patients (pts) with breast cancer (MAGENTA): Results on the genetic counselling experience

Background

Despite genetic testing (GT) and counselling (GC) being key in breast cancer (BC) risk assessment, GC uptake rates are low even among pts undergoing GT. A global survey was conducted among pts with BC to identify the gaps in the GC experience and to propose strategies to fill them.

Methods

A steering committee comprising of pts and pt advocates co-developed a 38-question survey, which was offered to pts in Argentina, Australia, Brazil, Egypt, India, Malaysia, Mexico, Russia and Taiwan in local languages, through social media. The questions pathway was dependent on response to prior questions. Chi-square test was used to assess significance between responses, if applicable.

Results

The final analysis set (FAS) included responses from 1176 respondents with a > 90% completion rate of survey questions. In the FAS, 737 (63%) respondents reported having undergone GT. Most respondents in the FAS (768/1061; 71%) rated their awareness level of GT/GC (before BC diagnosis) as between ‘very low’ to ‘moderate’. Among pts undergoing GT, 616 respondents responded to the question enquiring on the resources available to them to guide their GT experience, beyond their oncologist. These were the genetic counsellor (295/616; 48%), pt support groups (232/616; 38%) and websites (217/616; 35%). Among the 439 respondents who did not undergo GT, 174 (40%) were offered GT by their doctor but did not take it. The table shows the level of understanding of GC reimbursement eligibility among the respondents. Table: 311P

*Statistically significant difference (p<0.00001) between tested and not tested pts

Conclusions

Most pts with BC are not offered GC, which significantly correlates with GT uptake. Since poor awareness of GC is a critical gap, improving GC services and pt education through pt advocates and online tools may increase GT rates, offering a more impactful GT experience for pts and their families.

Clinical trial identification

Editorial acknowledgement

Professional medical writing assistance was provided by Madhubrata Ghosh, PhD, of Ward6 Singapore Pte Ltd, Singapore and funded by AstraZeneca.

Legal entity responsible for the study

AstraZeneca UK Limited.

Funding

AstraZeneca International (AstraZeneca UK limited).

Disclosure

R. Kaur: Financial Interests, Personal, Advisory Board: Pfizer, Novartis, Roche, AstraZeneca; Financial Interests, Personal, Invited Speaker: Pfizer, Novartis, Roche, AstraZeneca; Financial Interests, Personal, Research Grant: Pfizer, Novartis, Roche, AstraZeneca; Financial Interests, Institutional, Other: Pfizer, Novartis, Roche; Financial Interests, Personal, Advisory Board, Honoraria: Pfizer, Novartis, Roche, AstraZeneca; Financial Interests, Personal, Other, Congress participation, travel support, lectures: Pfizer, Novartis; Financial Interests, Personal, Training: Pfizer, Novartis; Financial Interests, Personal, Advisory Role: Pfizer, Novartis, Roche; Financial Interests, Personal, Speaker, Consultant, Advisor: Pfizer, Novartis, Roche, AstraZeneca; Financial Interests, Personal, Advisory Board, Congress participation, travel support, lectures: Roche; Financial Interests, Personal, Other, Congress participation, lectures: AstraZeneca; Financial Interests, Personal, Other: AstraZeneca. S.L. Powell: Financial Interests, Personal, Full or part-time Employment: Pink Hope; Financial Interests, Personal, Advisory Board, Honoraria: AstraZeneca; Non-Financial Interests, Personal, Other, Travel support: AstraZeneca. M. Artigas: Financial Interests, Personal, Advisory Board, Honoraria: AstraZeneca. I. Borovova: Financial Interests, Personal, Full or part-time Employment: Russian Association of Oncology Patients “ZDRAVSTVUY!”; Financial Interests, Personal, Advisory Board: Public Council under the Ministry of Health of the Russian Federation, Presidential Council for the Development of Civil Society and Human Rights, Public Council under Roszdravnadzor, Council for Social Welfare under the Government of the Russian Federation, AstraZeneca. P. Gadiya: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Role: AstraZeneca. A. Hsu: Financial Interests, Personal, Advisory Board, Honoraria: AstraZeneca. L. Kidd: Financial Interests, Personal, Full or part-time Employment: Victorian Department of Education, Beaconsfield Primary School; Financial Interests, Personal, Advisory Board, Honoraria: AstraZeneca. D. Rosenfeld: Financial Interests, Personal, Advisory Board: AstraZeneca. M.M. Saeed: Financial Interests, Personal, Advisory Board: AstraZeneca. E. Scarelli: Financial Interests, Personal, Full or part-time Employment: OncoGuia Institute; Financial Interests, Personal, Advisory Board: AstraZeneca, Pfizer, Novartis, Roche, MSD, Daiichi Sankyo, Bayer; Financial Interests, Personal, Advisory Board, Honoraria: AstraZeneca, Pfizer, Novartis, Roche, MSD, Daiichi Sankyo, Bayer; Financial Interests, Personal, Officer, Congress participation, lectures: AstraZeneca; Financial Interests, Personal, Invited Speaker: AstraZeneca, Pfizer, Roche, MSD, Daiichi Sankyo, Bayer; Financial Interests, Personal, Other, Congress participation, lectures: Pfizer, Roche, MSD, Daiichi Sankyo, Bayer; Financial Interests, Personal, Invited Speaker, Congress participation, lectures: Novartis; Financial Interests, Personal, Other: Novartis. M. Wahib: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca.